Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neuro-oncology

Survivorship & Monitoring: Life After Treatment

At a Glance

After astrocytoma treatment, long-term monitoring involves regular MRI scans tailored to your tumor's grade. Doctors use advanced imaging to distinguish true recurrence from treatment effects like pseudoprogression, while helping you manage side effects like fatigue and cognitive changes.

Transitioning into the survivorship phase of an astrocytoma journey is often a mix of relief and new challenges. While primary treatment (like surgery or radiation) may be behind you, “monitoring” becomes a long-term part of your life. The goal of this phase is to catch any changes early while managing the lingering effects of the therapies that helped control the tumor [1][2].

The Surveillance Schedule: What to Expect

Your monitoring schedule is not one-size-fits-all; it is tailored to the grade and molecular profile (like IDH status) of your tumor [3][4].

  • Grade 2 (Lower Risk): Initially, you may have an MRI every 3 to 6 months. If the tumor remains stable for several years, your doctor may extend the interval to once or twice a year [1][5].
  • Grade 3 and 4 (Higher Risk): Because these tumors are more aggressive, monitoring is typically more frequent, often occurring every 2 to 3 months for the first few years [3][6].

Understanding “Scanxiety”

It is common to experience a peak in emotional distress in the days leading up to an MRI and the days waiting for results—a phenomenon known as scanxiety [7][8]. While many patients feel reassured by a “clear” scan, the process itself can be a significant psychological burden [9][10]. Best practices to manage this include asking your doctor for a clear timeline of when results will be available and using relaxation techniques, such as mindfulness or even virtual reality interventions, to reduce distress [11][7].

Recurrence vs. Treatment Effects (Pseudoprogression)

One of the most confusing parts of survivorship imaging is pseudoprogression. This occurs when an MRI shows what looks like a growing tumor, but it is actually just inflammation or “radiation necrosis” (cell death) caused by your treatment [12][13].

To tell the difference, doctors use advanced tools beyond a standard MRI:

  • Perfusion MRI (pMRI): Measures blood flow. A true tumor recurrence usually has high blood flow (rCBV), while treatment effects typically have low blood flow [14][15].
  • Amino Acid PET Scans: Use specialized “tracers” (like FET-PET) that tumor cells absorb more than healthy tissue, helping confirm a diagnosis with high accuracy [16][17].

Managing Long-Term Side Effects

The treatments that save lives can sometimes leave lasting “signatures” on your health. Common late-onset effects include:

  1. Fatigue: This is the most frequently reported side effect and can persist for months or years [18].
  2. Cognitive Changes: You may notice subtle declines in memory, “mental fog,” or trouble finding the right words [19]. Techniques like hippocampal-avoidance radiation are often used to minimize this risk, and medications like memantine are sometimes used to protect cognitive function [20][21].
  3. Radiation Necrosis: In some cases, localized brain tissue can break down months or even years after radiation, sometimes requiring treatment with steroids or other medications to reduce swelling [13][22].

Monitoring is a partnership. By tracking how you feel and understanding the “why” behind your scan schedule, you can play an active role in your long-term health and peace of mind [23][10].

Common questions in this guide

How often will I need MRI scans after my astrocytoma treatment?
Your MRI schedule depends on the grade and molecular profile of your tumor. Grade 2 tumors typically require scans every 3 to 6 months, while higher-grade tumors may need monitoring every 2 to 3 months for the first few years.
What is pseudoprogression on a brain MRI?
Pseudoprogression happens when an MRI shows what looks like tumor growth, but is actually inflammation or cell death caused by your treatment. Doctors use advanced imaging, like perfusion MRI or PET scans, to tell the difference between treatment effects and true recurrence.
What are the long-term side effects of astrocytoma treatment?
Common late-onset effects include severe fatigue, cognitive changes like mental fog or memory issues, and radiation necrosis. Your healthcare team can offer interventions like specialized radiation techniques or medications to help manage these issues.
How can I manage anxiety before and after my MRI scans?
Scanxiety is a very common emotional response to upcoming imaging and waiting for results. You can manage it by asking your doctor for a clear timeline of when results will be available and using relaxation techniques such as mindfulness.
What is radiation necrosis?
Radiation necrosis is the breakdown of localized brain tissue that can occur months or even years after radiation therapy. It can cause swelling in the brain and is often treated with steroids or other medications to reduce inflammation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific tumor grade (2, 3, or 4) and molecular markers, how frequently will I need MRI scans?
  2. 2.If a scan shows a new area of enhancement, what 'advanced' imaging (like Perfusion MRI or PET) does this center use to distinguish recurrence from treatment effects?
  3. 3.Are there supportive care services, like neuropsychology or specialized counseling, available to help me manage cognitive changes or 'scanxiety'?
  4. 4.What 'red flag' symptoms should I look for that would warrant a scan sooner than my scheduled appointment?
  5. 5.Is there a way for me to get my results faster to minimize the waiting period after my scan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Early atypical malignant transformation of diffuse low-grade astrocytoma: The importance of genotyping.

    Valente Aguiar P, Sousa O, Silva R, et al.

    Neurocirugia 2020; doi:10.1016/j.neucir.2020.09.003.

    PMID: 33162332
  2. 2

    The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01.

    Kim YZ, Kim CY, Wee CW, et al.

    Brain tumor research and treatment 2019; (7(2)):74-84 doi:10.14791/btrt.2019.7.e43.

    PMID: 31686437
  3. 3

    Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.

    Lee D, Riestenberg RA, Haskell-Mendoza A, Bloch O

    Journal of neuro-oncology 2021; (152(1)):89-98 doi:10.1007/s11060-020-03677-4.

    PMID: 33389563
  4. 4

    Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.

    Fortin Ensign SP, Jenkins RB, Giannini C, et al.

    Neuro-oncology 2023; (25(1)):28-36 doi:10.1093/neuonc/noac205.

    PMID: 35973817
  5. 5

    Rapid malignant transformation of low-grade astrocytoma in a pregnant woman.

    Hanada T, Rahayu TU, Yamahata H, et al.

    The journal of obstetrics and gynaecology research 2016; (42(10)):1385-1389 doi:10.1111/jog.13072.

    PMID: 27356501
  6. 6

    Plasma-Derived Extracellular Vesicles Reveal Galectin-3 Binding Protein as Potential Biomarker for Early Detection of Glioma.

    Rana R, Chauhan K, Gautam P, et al.

    Frontiers in oncology 2021; (11()):778754 doi:10.3389/fonc.2021.778754.

    PMID: 34900729
  7. 7

    Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.

    King AL, Acquaye-Mallory AA, Vera E, et al.

    BMC cancer 2023; (23(1)):262 doi:10.1186/s12885-023-10671-2.

    PMID: 36944930
  8. 8

    Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.

    King AL, Acquaye AA, Mendoza T, et al.

    Research square 2023; doi:10.21203/rs.3.rs-2521990/v1.

    PMID: 36865245
  9. 9

    Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

    Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

    Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

    PMID: 39343818
  10. 10

    "Scanxiety" and a sense of control: the perspective of lung cancer survivors and their caregivers on follow-up - a qualitative study.

    Seibel K, Sauer B, Wagner B, Becker G

    BMC psychology 2023; (11(1)):119 doi:10.1186/s40359-023-01151-0.

    PMID: 37069692
  11. 11

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  12. 12

    Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.

    Sidibe I, Tensaouti F, Roques M, et al.

    Biomedicines 2022; (10(2)) doi:10.3390/biomedicines10020285.

    PMID: 35203493
  13. 13

    Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

    Pires da Silva I, Glitza IC, Haydu LE, et al.

    Pigment cell & melanoma research 2019; (32(4)):553-563 doi:10.1111/pcmr.12775.

    PMID: 30767428
  14. 14

    Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas.

    Carrete LR, Young JS, Cha S

    Frontiers in neuroscience 2022; (16()):787755 doi:10.3389/fnins.2022.787755.

    PMID: 35281485
  15. 15

    Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques.

    van Dijken BRJ, van Laar PJ, Smits M, et al.

    Journal of magnetic resonance imaging : JMRI 2019; (49(1)):11-22 doi:10.1002/jmri.26306.

    PMID: 30561164
  16. 16

    Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.

    Werner JM, Weller J, Ceccon G, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(13)):3704-3713 doi:10.1158/1078-0432.CCR-21-0471.

    PMID: 33947699
  17. 17

    FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation.

    Lohmann P, Elahmadawy MA, Gutsche R, et al.

    Cancers 2020; (12(12)) doi:10.3390/cancers12123835.

    PMID: 33353180
  18. 18

    Quality of life and efficacy of temozolomide combined with whole-brain radiotherapy in patients with brain metastases from non-small-cell lung cancer.

    Lv Y, Zhang J, Liu Z, et al.

    Molecular and clinical oncology 2018; (9(1)):70-74 doi:10.3892/mco.2018.1622.

    PMID: 29977541
  19. 19

    Memantine for Prevention of Brain Irradiation-Induced Cognitive Toxicity: A Tale of an Underappreciated and Underused Intervention.

    Chilukuri S, Burela N

    JCO global oncology 2020; (6()):1384-1388 doi:10.1200/GO.20.00342.

    PMID: 32926643
  20. 20

    Efficacy of Hippocampal Avoidance Whole Brain Radiotherapy to Preserve the Cognitive Functions among Brain Metastasis Patients: Systematic Review and Meta-analysis.

    Surendran HP, Sah SK, Veeralakshmanan P, et al.

    Neurology India 2025; (73(3)):429-445 doi:10.4103/neurol-india.Neurol-India-D-24-00727.

    PMID: 40408570
  21. 21

    Role of memantine to mitigate radiation-induced cognitive dysfunction in brain metastasis patient receiving whole brain radiotherapy: a systematic review.

    Oktavianda YD, Permata TBM

    Radiation oncology journal 2024; (42(4)):281-294 doi:10.3857/roj.2024.00269.

    PMID: 39748529
  22. 22

    Whole brain radiation therapy resulting in radionecrosis: a possible link with radiosensitising chemoimmunotherapy.

    Ngu S, Werner C, D' Amico RS, Wernicke AG

    BMJ case reports 2023; (16(11)) doi:10.1136/bcr-2023-256758.

    PMID: 38016763
  23. 23

    Qualitative study: patients' and parents' views on brain tumour MRIs.

    Tyldesley-Marshall N, Greenfield S, Neilson S, et al.

    Archives of disease in childhood 2020; (105(2)):166-172 doi:10.1136/archdischild-2019-317306.

    PMID: 31391153

This page provides information on astrocytoma survivorship and monitoring for educational purposes only. Always consult your neuro-oncologist to determine the safest and most appropriate follow-up schedule and care plan for your specific condition.

Get notified when new evidence is published on Astrocytoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.